Antibody Array Platform for CRS Cytokine Analysis

Are unpredictable CRS severity, limited sample availability, and slow biomarker turnaround hindering the clinical translation of your immunotherapies? Creative Biolabs' Antibody Array Platform for CRS Cytokine Analysis delivers rapid, high-fidelity immune profiling using high-throughput, multiplexed antibody arrays. We provide the high-content data and expert interpretation necessary to de-risk development and advance your most promising candidates with confidence.

Introduction

Cytokines function as critical signaling molecules whose dynamic changes directly reflect the host's immune status and therapeutic response. Thus, precise and systematic analysis of these cytokines is essential for evaluating treatment efficacy and monitoring adverse effects. Antibody microarray technology operates on the principle of immobilizing highly specific antibodies on a solid-phase surface, enabling simultaneous quantitative analysis of multiple target proteins in complex biological samples through parallel detection. Recent studies demonstrate that a CRS-focused cytokine analysis system based on antibody microarray platforms not only allows real-time, multi-parameter monitoring but also provides crucial technical support for early warning and the development of intervention strategies.

Fig.1 Antibody microarray applications in cellular immunology.¹

Antibody Array Platform for CRS Cytokine Analysis at Creative Biolabs

Creative Biolabs' Antibody Array Platform for CRS Cytokine Analysis revolutionizes cytokine detection by offering an unprecedented level of sensitivity and precision. Our innovative system empowers you to efficiently and accurately profile the expression levels of a multitude of cytokines at the protein level, with detection capabilities down to the picogram per milliliter range.

What we can offer

Our cytokine analysis services leverage a suite of advanced antibody array platforms, each designed to address specific research needs:

Our Service Process

Required starting materials:

• Patient Serum/Plasma: Ideally, paired samples collected pre-treatment and at peak CRS timepoints for differential analysis.
• Cell Culture Supernatant: Samples from in vitro models (e.g., CAR T-cell co-culture assays) to establish baseline reactivity.
• Clinical/Study Metadata: Detailed information on CRS grading, therapeutic interventions, and clinical outcomes for proper data interpretation.

Key Steps:

Final Deliverables:

• Normalized Data Report: Comprehensive Excel file containing normalized relative protein expression levels.
• Differential Cytokine Profile Report: Detailed summary identifying key up- and down-regulated biomarkers, complete with statistical significance and fold-change calculations.

Key Advantages

• Comprehensive, High-Throughput Screening: Simultaneous analysis of various cytokine and chemokine targets from a single, low-volume sample, providing the definitive, multi-dimensional view necessary to profile the full cytokine release syndrome cascade.
• Custom Array Design for Specific Pathways: Leverage our proprietary library of thousands of validated antibodies to create custom arrays tailored precisely to your therapeutic pathway, mechanism of action (MoA), or specific preclinical model.
• Minimal Sample Volume Requirement: Expertise in handling highly constrained clinical specimens, enabling quantitative profiling using as little as of patient plasma or precious CSF, ensuring you maximize data from every valuable patient cohort.

FAQ

Why Choose Us?

Our platform is engineered to deliver unparalleled depth and reliability in cytokine profiling, specifically to deconvolute the complex immunobiology of CRS and related neurotoxicities. We empower your research with a platform that moves beyond simple cytokine detection to provide a spatially and statistically robust understanding of the immune response, enabling confident decision-making in development process.

Customer Reviews

"Using Creative Biolabs' Antibody Array Platform for CRS analysis in our research has significantly improved the confidence in our CNS safety profile. We were able to confirm that localized neuroinflammation markers, not visible in serum, were present in CSF samples, facilitating our IND submission."— Dr. Al*n, Research Lead.

"The minimal volume requirement was essential. We achieved the necessary statistical power for over 300 targets using a fraction of the precious clinical samples we had budgeted for, accelerating our data lock by two weeks."— P. L*n, Clinical Operations.

"We were specifically looking to confirm that our candidate was inhibiting the CCL3/CCL4 pathway. The high-resolution data provided by Creative Biolabs was quantitative and statistically robust, providing irrefutable evidence of our drug's desired mechanism of action, even in the presence of systemic signal noise."— Dr. M*s, Immunology Director.

How to contact us?

Ready to gain the definitive profile of your therapeutic agent's immune impact? Contact our scientific team directly to discuss your project's needs and receive a detailed proposal.

Reference

1. Chen, Ziqing et al. "Current applications of antibody microarrays." Clinical proteomics vol. 15 7. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s12014-018-9184-2.